Immunitor
Vancouver
British Columbia
Canada
Tel: 360-566-2194
Website: http://www.immunitor.com/
Email: info@immunitor.com
About Immunitor
Immunitor Inc. is a privately held, Vancouver headquartered commercial stage biopharmaceutical company (www.immunitor.com) with offices in Beijing, Johannesburg, Moscow and Ulaanbaatar. Immunitor's strength resides in its proprietary oral vaccine platform validated by numerous clinical trials conducted over the past 15 years. Immunitor makes several immunotherapy products addressing major health problems, i.e., in infectious diseases area: HIV, HBV, HCV, influenza, malaria, fungal and microbial infections including tuberculosis; in the area of autoimmune and metabolic diseases: i.e., allergy, renal failure, thyroiditis, Alzheimer disease, hypertension, atherosclerosis, obesity and diabetes; and recently in oncology space, with several candidates currently being investigated. They are all based on clinically proven rationale that regulation of disease-associated inflammation produces therapeutic benefit.YEAR FOUNDED:
2000
LEADERSHIP:
CEO: Aldar S. Bourinbaiar
PRODUCTS:
All Products
FOLLOW IMMUNITOR:
Tweets by Immunitor
12 articles about Immunitor
-
Key Capital HAP-V+ Immune Supplement Reported Effective Against COVID-19, and Colds and Flu
4/26/2021
KEY CAPITAL CORPORATION advises that Immunitor, its Licensing partner, continues to receive favorable reports from people in Asian and African countries using the Immunitor HAP-V+ Immune Supplement in cases of respiratory infections.
-
Key Capital to Fast-track Breakthrough Liver Cancer Immunotherapy
12/1/2020
KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that in association with Immunitor Inc, the Company will seek to fast-track further clinical studies and regulatory approval of the FDA Orphan Drug Designated Immunitor V5 as a development priority. Immunitor V5 has demonstrated unparalleled success in all clinical studies to date for the treatment of liver cancer, which is p
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Immunitor Release: Key Capital Announces Terminal Liver Cancer Trial Results Publication
4/13/2017
-
Immunitor Release: Key Capital Corporation Announces Immunotherapy Product Rights Agreement
3/7/2017
-
Immunitor's Breakthrough In Cancer Immunotherapy
6/25/2014
-
Immunitor USA Inc. CEO Joins Immune Network Ltd. Board of Directors
2/14/2011
-
Immunitor USA Inc. Publishes Interim Data From Phase IIB Imm01 TB Trial
12/30/2010
-
Immunitor USA Inc.r Completes Business Trip to China and Presents at Chinese Academy of Science Annual TB Meeting
12/13/2010
-
Immunitor USA Inc. Awarded the Key U.S. Patent Related to Oral Vaccine Technology Platform
11/29/2010
-
Immunitor USA Inc.'s V5 Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week
11/1/2010
-
Immunitor USA Inc. Release: Bird Flu Oral Vaccine Licensed By MDM Group
3/14/2006